Amphastar Pharmaceuticals, Inc.AMPH
What Amphastar Pharmaceuticals, Inc. does.
We are a biopharmaceutical company focusing on developing, manufacturing, and commercializing technically challenging generic and proprietary injectable, inhalation, and intranasal products, as well as active pharmaceutical ingredient, or API products. We currently manufacture and sell over 25 prescription pharmaceutical products, and an over-the-counter product, Primatene MIST ® .
Our largest products by net revenues currently include BAQSIMI ® glucagon nasal powder, or BAQSIMI ® , Primatene MIST ® , glucagon, epinephrine, and lidocaine.
In June 2023, we completed our acquisition of BAQSIMI ® , the first and only nasally administered glucagon for the treatment of severe hypoglycemia in people with diabetes, and it is currently available in the United States and 26 international markets.
Revenue and profit, by fiscal year.
| Fiscal year | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Revenue | $349.8M | $437.8M | $499.0M | $644.4M | $732.0M | $719.9M |
| Net income | $1.4M | $62.1M | $91.4M | $137.5M | $159.5M | $98.1M |
| Free cash flow | $23.4M | $70.5M | $65.1M | $145.3M | $172.3M | $121.2M |
More on AMPH.
- Amphastar Pharmaceuticals, Inc. summary
- Amphastar Pharmaceuticals, Inc. financial statements
- Amphastar Pharmaceuticals, Inc. key metrics
- Amphastar Pharmaceuticals, Inc. health scores and style box
- Amphastar Pharmaceuticals, Inc. earnings
- Amphastar Pharmaceuticals, Inc. dividends
- Amphastar Pharmaceuticals, Inc. valuation
- Amphastar Pharmaceuticals, Inc. ownership and insiders
- Amphastar Pharmaceuticals, Inc. peers
Figures from Amphastar Pharmaceuticals, Inc.'s filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.